CD274 and head and neck squamous cell carcinoma: Pembrolizumab also was approved alongside chemotherapy (platinum and fluorouracil) for all HNSCC patients and received approval as a single-agent therapy for patients PD-L1-positive patients with CPS ≥ 1 [123].